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Assessing severity of anaphylaxis: 
a data-driven comparison of 23 instruments
Esben Eller1* , Antonella Muraro2, Ronald Dahl1,3, Charlotte Gotthard Mortz1 and Carsten Bindslev‑Jensen1
Abstract 
Backgroud: The severity of an allergic reaction can range from mild local symptoms to anaphylactic shock. To score 
this, a number of instruments have been developed, although heterogeneous in design and purpose. Severity scor‑
ing algorithms are therefore difficult to compare, but are frequently used beyond their initial purpose. Our objective 
was to compare the most used severity scoring instruments by a data‑driven approach on both milder reactions and 
anaphylaxis.
Methods: All positive challenges to foods or drugs (n = 2828) including anaphylaxis (n = 616) at Odense University 
Hospital, Denmark from 1998 to 2016 were included and severity was scored according to Sampson5. Based on rec‑
ommendations from an expert group, the symptoms and values from Sampson5 were for all reactions and anaphy‑
laxis only translated and compared by kappa statistics with 22 instruments, ranging from 3 to 6 steps.
Results: For milder reactions, there was a significant correlation between the number of steps in an instrument and 
the number of challenges that could be translated, whereas all instruments were good to identify food anaphylaxis. 
Some instruments scored reactions more severely than Sampson5, other scored them milder and some scored food 
and drug challenges differently. Instruments for hymenoptera reactions were difficult to apply on food and drug 
reactions, and thus distributed severity differently. Algorithms hampered the translation between instruments, and 7 
instruments were poor concerning drug anaphylaxis, including the only instrument developed specifically for drug 
reactions.
Conclusion: The distributions of severity differed between the 23 instruments in both food and drug allergy, and 
thus rendering translation especially between scoring systems with 3 and 5 grades difficult. Fine‑graded and sim‑
ple instruments are preferred for comparison especially among milder reactions, and instruments applied to non‑
intended situations may not reflect a true severity picture.
Keywords: Severity assessment, Anaphylaxis, Severity comparison, Kappa statistics
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The severity of an allergic reaction can range from sub-
jective local symptoms to lethal anaphylactic shock. 
Dosage, individual threshold, route of exposure, type of 
allergen, age, comorbidity and involvement of facilitators 
can influence the severity, and this combined with the 
progression of symptoms and the ambiguous definition 
of anaphylaxis [1], makes severity difficult to capture. 
Furthermore, the settings in which the reaction occurs 
are far from comparable, ranging from accidental expo-
sure in an unknown environment to controlled chal-
lenges in a highly specialized clinical setting.
Multiple scoring instruments have been developed to 
assess the overall severity of an allergic reaction, elicited 
either by foods [2–9], drugs [10] or hymenoptera stings 
[11–14]. All instruments cover the whole spectrum of 
symptoms and signs, and several are using the term ana-
phylaxis to describe their scoring algorithm, although it 
is evident that non-anaphylactic milder symptoms nei-
ther fulfill the WAO [1, 15] nor the new ICD-11 [16] 
criteria. Many of these instruments are today applied 
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beyond their initial purpose, whereas others have been 
adopted to span multiple causes [17–21]. Data-driven 
instruments are scarce [5, 9, 22] and the majority of tools 
are designed empirically for data collection in emer-
gency rooms (ER) or intensive care units (ICU) [10, 13, 
14, 17–20], in clinical trials (CT) [4, 6, 7, 12], or based 
on consensus reports, theoretical reviews, position 
papers, or national guidelines [8, 21, 23–27]. All instru-
ments have organ-specific outcomes, dividing symptoms 
according to their anatomical origin, i.e. skin, respiratory, 
gastro-intestinal (GI), cardio-vascular (CV) or neurologi-
cal symptoms. Some use a detailed predefined “symptom 
list, ranging from a binary form of “present/not present” 
to detailed grading of specific symptoms, e.g. urticaria, 
into mild/local or severe/generalized. Others use more 
general ‘catch-all’ symptoms from a specific organ, e.g. 
all symptoms related to the “GI tract”. All operate with 
an ordinal scale spanning over 3–6 incomparable steps, 
where the overall severity either is defined by the high-
est numerical value, i.e. most severe symptoms [7, 8, 10, 
11, 14, 17, 21, 23–25], relative allergen exposure [6, 18], 
milder symptoms obligate for severity progressing [4], 
fulfillment of “2-or-more” [13], summation of symptoms 
to get severity [12, 28] or related to number of organs 
involved [2, 5, 9, 27, 29].
The ideal severity assessing instrument should span all 
ages (children/adolescents/adults), all allergens (foods, 
insects, drugs), all exposure circumstances (exercise 
and other co-factors, injection, inhalation, oral intake 
etc.) and cope with the whole spectrum of symptoms. 
This instrument should work as a measuring tool for 
patients and clinicians, applicable in primary care, ER/
ICU, research projects, and combining existing instru-
ments, i.e. being retrograde compatible. A prospective 
comparison between existing instruments, applied in situ 
at the same exposure or on the same patient, would be 
ideal, but this is time consuming, raises ethical dilemmas 
on when to treat with adrenalin due to ambiguous stop-
criteria and does not solve the issue of precise definition 
of existing tools. Knowing that titrated challenges are 
not ideal for addressing severity of anaphylaxis, a retro-
spective data-driven validation, comparing instruments 
based on robust clinical challenge-verified data could be 
the second best option to compare the translatability and 
distribution of severity between instruments, and could 
form basis for development of a common standardized 
instrument.
Our aim was retrospectively to compare the distribu-
tion of severity in existing grading instruments, by apply-
ing each of them to a well-characterized clinical database 
covering both anaphylactic and milder reactions, based 
on the definition of an expert-group within the fields of 
dermato-allergology, respiratory-allergology and pediat-
ric allergology. Ideally, we would provide a platform for 
subsequent development of a universal scoring instru-
ment for anaphylactic reactions. This study is neither 
testing the efficacy of intruments to identify anaphylaxis, 
nor should it be seen as a literature overview of existing 
severity assessing instruments, but instead as a compari-
son of the, to our knowledge, most used instruments.
Methods
Data, i.e. recorded objective signs and/or subjective 
symptoms, from all positive food (n = 2382) or drug 
challenges (n = 466) at the Odense Research Center for 
Anaphylaxis (ORCA) from January 2001 to January 2016 
were consecutively entered into a database and included. 
Anaphylaxis according to WAO criteria [15] was seen in 
22% (535/2382) of the food challenges and 19% (84/446) 
of the drug challenges. Egg (n = 720), peanut (n = 579), 
hazelnut (n = 264) and milk (n = 230) were the most fre-
quent food allergens, whereas penicillin accounted for 
2
/
3 and non-steroidal, anti-inflammatory, drug (NSAID) 
for 1
/
3 of the drug challenges (see Table 1).
The most frequently recorded symptoms after food 
challenges were urticaria (47%), oral allergy syndrome 
(OAS) (35%), abdominal pain (32%), conjunctivitis 
(24%), vomiting (24%) and rhinorrhea (22%). For drug 
Table 1 Characteristics of included challenges and severity distribution of Sampson5 for foods and drugs challenges
a According to WAO [15]
n # Allergens Mean age 
(years [SD])
Gr. 1 Gr. 2 Gr. 3 Gr. 4 Gr. 5
Total 2848 114 17.6 [18.4] 296 (10%) 1253 (44%) 843 (30%) 416 (14%) 20 (1%)
Foods  (anaphylaxisa) 2382 (535) 86 11.6 [4.0] 198 (0) 1026 (0) 800 (177) 347 (347) 11 (11)
 0–3 years 859 22 2.3 [1.0] 33 (4%) 422 (49%) 285 (33%) 118 (14%) 1 (0%)
 4–15 years 990 43 7.8 [3.0] 59 (6%) 384 (39%) 408 (41%) 136 (14%) 3 (0%)
 15+ years 533 73 33.9 [14.0] 106 (20%) 220 (41%) 107 (20%) 93 (17%) 7 (1%)
Drugs  (anaphylaxisa) 446 (84) 28 43.8 [17.3] 98 (0) 227 (0) 43 (6) 69 (69) 9 (9)
 Antibiotics 285 21 44.6 [17.7] 79 (28%) 154 (54%) 24 (8%) 21 (7%) 7 (2%)
 NSAID 143 7 41.1 [16.8] 15 (10%) 69 (48%) 16 (11%) 41 (29%) 2 (1%)
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challenges, skin symptoms were predominant; either 
localized or generalized pruritus (47%), urticaria (36%), 
rash (35%) or angioedema (17%) (Fig. 1).
The overall severity (Table  1) was based on Samp-
son5 [8] with an addition of 3 milder symptoms 
including upper airways and/or eyes (itchy eyes/nose, 
conjunctivitis) and abdominal pain. Patients chal-
lenged to food were significantly younger than patients 
challenged to drugs (p < 0.001), and food-challenges 
were therefore subdivided into 3 age-categories (0–3, 
4–15, and + 15  years). There was a significant dif-
ference between the distribution of severity grad-
ing between the 3 age-classes (p < 0.001). Children in 
the 0–3  years group rarely had subjective symptoms, 
such as OAS, abdominal pain or nausea, whereas 63% 
of them had urticaria and/or rhino-conjunctivitis, 
resulting in often having their challenge stopped after 
a grade 2 reaction (p < 0.001), compared to older age 
groups (4–15 years/+ 15 years). Group + 15 years was 
even more polarized in its severity grading, i.e. often 
significantly (p < 0.001) milder (gr. 1) symptoms, char-
acterized by a generally higher level in subjective skin 
symptoms and abdominal pain, but also more frequent 
severe reactions (gr. 4–5) (p < 0.001). This effect dis-
appeared after adjustment for specific allergens (i.e. 
milk, egg, peanut, hazelnut) and was entirely driven by 
more severe objective reactions after a challenge with 
peanuts [a-OR (95% CI) = 1.77 (1.33–2.35)]. In the 
+ 15  years group, food challenges were significantly 
milder (p = 0.03) than drug challenges. Reactions to 
NSAID were more severe than antibiotics (p < 0.0001), 
caused by more frequently respiratory distress, espe-
cially laryngeal and lower respiratory symptoms 
(p < 0.001).
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Fig. 1 Percentage of challenges with recorded specific symptoms after foods (a) and drugs (b). Food challenges are age‑divided into 0–3, 4–15 and 
15+ years, whereas drug‑challenges are divided into antibiotics and NSAID’s
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Translation of symptoms to other instruments
A direct literature-search identifying severity instru-
ments was not feasible, since the majority of instruments 
were not published as such, but developed as tools for 
specific use, e.g. to address severity of reactions in aller-
gen immune therapy trials. Included instruments were 
therefore identified empirically or in relation to the 
European Academy of Allergy and Clinical Immunol-
ogy (EAACI) taskforce initiative on Food Allergy and 
Anaphylaxis [30]. We identified 22 previously published 
instruments focusing on severity of allergic reactions [2, 
4, 6, 7, 9–14, 17–21, 23–29]; however, 2 were excluded 
for not addressing the overall severity but more listing 
symptoms [19, 26]. Moreover, the new EAACI taskforce 
guidelines [30] (newEAACI3), a 3-step organ-specific 
“catch-all” instrument and the new iFAAM oFASS instru-
ment [5], a 5-step observational instrument (iFAAM5) 
were included. With Sampson5 [8], a total of 23 instru-
ments were compared (Table 2).
Numerical values for symptoms in Sampson5 (e.g. 
value 2 for generalized urticaria) were then retrospec-
tively translated according to recommendations by the 
expert group into the corresponding value in the com-
paring instruments (e.g. value 1 in Mueller4 [13]). As 
Table 2 Overview of  the  22 included studies, their origin and  exact numerical value (1–6) for  each listed symptom 
ordered by organ and appearance in Sampson5
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Pub. Year 2003 Upbl. 2016 2013 2001 2006 1959 1977 1999 1996 2013 2010 2011 1992 2004 2013 2007 1997 2005 1990 1998 2018 2004
Ref. [8] [5] [29] [28] [4] [2] [13] [10] [21] [20] [23] [27] [9] [14] [17] [18] [25] [7] [6] [12] [11] [30] [24]
No. of grading steps 5 5 6 6 5 5 4 4 4 4 4 4 3 3 3 3 3 3 3 3 3 3 3
Target Allergen Food All Food Pea. Pea. Ven. Drugs All All All SCIT Pea. Ven. All All All Pea. Pea. Ven. Ven. All All
Target group Ped. All Ped. All Ped. All All All All All Ped. All All All Ped. Ped. Ped. Adults Adults All All
n 253 88 60 84 69 172 161 220 1149 402 40 171 74
Other Org.+Alg Alg. Alg. Alg. Alg. Alg. Alg. Alg. Alg. Amnt. Amnt. Alg. Org.
Recruitment Rev. Cons. Cons. N.A. CT CT ICU ICU Rev. ER Cons. Conc. CT ICU ICU ICU Rev. CT CT CT CT Cons. Conc.
Localized pruritus 1 2 (1) 1 1* 1
Generalized pruritus 2‡ 3 (4) 1 2 1(2†) 2* 1 1 1 (2) 1
Localized urcaria 1 2 (1) 1 1(3†) 1 1 1 (2) 1*
Generalized urcaria 2‡ 3 (4) 2 2(3†) 1 2 (3) 1(2†) 2 1 1 1 2 1 2* 1
Localized angioedema / mild lip swelling 1 1 2 (1) 1 1 1(2†) 1 1 1*
Generalized angioedema 2‡ 2(3†) 3 (4) 2 1 2 (3) 1(2†) 2 1 1 1 2 (3) 1 2* 1
Localized flushing 1 1 2 (1) 1 1* 1*
Generalized flushing 2‡ 2(3†) 3 (4) 2 1(2†) 2* 1 (2) 1* 1 2* 1
Itchy eyes / nose Sub 1†† 2(3†)* 1 3* 1(3†) 1 1(2†) 3* 1 2* 1*
Sneezing Obj 2 2(3†)* 1 3* 1(3†) 1 1(2†) 3* 1 2* 1*
Nasal congeson 2 1(2†)
Marked congeson 3
Rhinorrhea Obj 3 2(3†)* 2 3* 1(3†) 2 1 1(2†) 3* 1 2* 1*
Conjucvis Obj 2†† 5* 3* 1(3†) 3 (1 3) 1(2†) 3* 2* 1*
Sensaon of throat pruritus or thightness Sub 3‡ 4* 1 4 1 1(2†) 3* 1 2 2 1* 1
Barky cough, Hoarseness, difficulty swallowing Obj 4‡ 4* 4 5 (2–5) 4 4 (2) 3 3 (2) 2 (1) 3 (2) 3 (2) 3* 3 2 2 2 3 2 2 3* 2
Wheezing / Asthma / Dyspnea /Cyanosis Obj 4‡ 4* 4 (5) 5 (3 6) 4 (5) 4 (2) 3 (2) 3 (2) 3 (2) 2 (1 3) 3 (2 4) 3 (2) 3* 2 2 (3) 2 (3) 2 (1 3) 3 (2) 3 2 2 3* 2 (1 3)
Respiratory arrest Obj 5‡ 4* 6 6 5 4 4 4 4 4 3* 3 3 3 3* 3
Oral pruritus, oral “ngling” Sub 1 2(3†)* 1*11*211111
Abdominal pain Sub 2†† 2(3†)* 2(3†) 3 (2 5) 3* 2 (1) 2 2* 2 2 (1) 2* 2 2 2 (1) 2 (3) 2* 2* 2 (1)
Nausea Sub 2 2(3†)* 2(3†) 3 (2) 3* 2 2* 2 1 1(2†) 2* 2 1 2* 2* 1
Emesis x’s 1 2 13 11 2 (3) 1
Repeve voming 3‡ 4 (5) 2 (3) 2 2 2 (3) 2
Diarrhea 4‡ 1 2 2
Loss of bowel control 5‡ 2 (3) 4 3 3
Mild hypotension (90-110 mm Hg) 4‡ 4 5 2 2 1 2
Hypotension (<90 mm Hg) 5‡ 5* 5 6 4 3 3 2 4 3 3 2 3 3 3 3 3 3* 3
Tachycardia (increase >15 beats/min) 3‡ 4 5 2 2 1 1
Dysrhythmia 4‡ 5 5* 3 2 4 3 3*
Severe bradycardia 5‡ 6 6 5 5* 4 4 4 (3) 4 4 3 3 3 3 3 3 3 3* 3
Change in acvity level Sub 2 2 (1) 1 1 2 (1 3) 3* 2
Change in acvity level plus anxiety 3 5* 4 (3) 2 1 1
Feeling of “pending doom”, light headedness 4 5* 5 5 3 3 (4) 3 2 (3) 3 3* 2
Loss of consciousness Obj 5‡ 5* 6** 6 (5) 5 5** 4 4** 4** 2 (3) 4 4 3* 3 3 3 3 3 3** 3 3 3* 3
Inconnence Obj 4 4 3 3 3
Fever Sub 1 1
Uterus sub 3 3 1-3 2
Type B No. of missing symptoms 4 11 3 8 13 20 13 11 13 6 12 0 21 20 23 7 24 21 18 27 7 7
of all reacons (Food / Drug) 100/98 96/93 99/99 98/87 89/84 85/62 90/91 95/97 86/85 99/98 84/70 100/100 67/87 85/68 83/61 96/78 64/75 87/78 87/80 58/50 99/90 97/78
of anaphylaxis (Food / Drug) 100/100 100/94 100/100 100/100 98/88 99/94 98/83 100/94 100/100 100/100 96/87 100/100 94/85 99/99 98/87 100/100 91/70 98/88 100/90 94/94 100/100 100/100
Type C Symp. with reduced informaon (red) 12 8 4 8 8 2 12 12 2 10 4 0 0 2 2 2 6 0 10 0 6 4
Type D Symp. with increased informaon (green) 0 1 16 1 3 1 1 3 8 5 2 0 0 2 1 2 1 6 0 0 0 1
Translatabily
(% of Sampson5)
Lower Resp
Type A
Neuro
CV
GI
2
2
11
13*
2*
1 11*
2 2
11*112(3†)*
2(3†)*
Obj 2(3†) 1211*12(3†)*
1*
1*
1
Skin
Laryngeal
Obj
Upper Resp Obj
Obj
Sub
2(3†) 3*
Obj
1*
2(3†)*
2*
1*
2(3†) 2 2* 3
3 3*
2(3†) 1* 1
2(3†)* 3*
2(3†)*
2* 1*
1 1* 1 1
2*
2(3†)*
445jbO
2* 2**23*2
3*
23Obj
Obj
*1buS
3*
3*
5*
–
–
– – – –
–
–
General discrepancies (Type A–D error) between Sampson5 and the comparing instrument are listed below; symptoms missing in Sampson5 (Type A), symptoms 
missing in the comparing instrument (Type B), symptoms where comparing instrument contained less information than Sampson5 (Type C—symptoms marked in 
red), and symptoms with increased information in comparing instrument compared to Sampson5 (Type D—marked in green)
Pea peanut, Ven venom, Ped only pediatric, Alg inbuilt algorithm, Amnt allergen amount depended, Org organ specific, Rev review, Cons consensus, CT clinical trial, ICU 
intensive care unit, ER emergency room, GI gastro-intestinal, CV cardio-vascular, Neuro neurological, Resp respiratory
*Unspecific “catch-all” symptom
**Added variables to reduced number of Type B error among the most severe cases
† Translation depending of number of involved organs
†† Added variables form Sampson5
‡ Anaphylaxis according to WAO [15]
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illustrated in Table 2, we identified 4 types of systematic 
translational errors (A–D). Type A errors were symp-
toms missing in Sampson5, i.e. “incontinence” or “fever”, 
whereas type B were missing variables in the comparing 
instrument and therefore untranslatable (i.e. localized 
urticaria in Mueller4 [13]). Sampson5 includes a total of 
23 symptoms from 7 “organs” with a total of 34 possible 
outcomes. Zee3 [9] was, due to its unspecific “catch-all” 
structure, the only instrument which embraced all symp-
toms covered by Sampson5, whereas no other instrument 
showed complete translatability; the best overlap was 
32/34 with ASCI6 [28] and poorest overlap was 8/34 with 
Golden3 [11]. Type B errors reduced the translatability, 
i.e. the percentage symptoms translated compared to 
Sampson5 (Table 2) and additionally led to a systematic 
discrepancy in those cases, where the most severe symp-
toms were missing, and thereby determining the overall 
severity by less severe symptoms; half of the recorded 
grade 5 reactions were caused by fainting, a symptom 
missing in 5 instruments [2, 6, 10, 21, 29], resulting either 
in downgrading to other less severe symptoms or being 
completely lost in translation. “Unconsciousness” was 
therefore added to these 5 instruments (marked ** in 
Table  1), corresponding to the highest numerical value 
for each system. Other errors were type C, where infor-
mation was lost, because the comparing instrument 
contained fewer variables than Sampson5, i.e. “local 
urticaria” or “generalized urticaria” reduced to “urti-
caria” (marked in red in Table  1). Finally type D, where 
the comparing instrument incorporated more infor-
mation than Sampson5, resulting in a translation based 
on expert interpretation, i.e. whether “wheeze, asthma, 
dyspnea, cyanosis” should be translated into “mild 
wheeze” or “pronounced dyspnea” (green in Table  1). 
“Catch-all” symptoms, e.g. “all symptoms from GI” were 
encountered to embrace all possible symptoms for that 
specific organ. Sampson5 included the lower respiratory 
symptom “wheeze/asthma/dyspnea/cyanosis”, which was 
translated into “asthma” in cases with multiple unambig-
uous translation possibilities, e.g. “wheeze”, “asthma”, or 
“cyanosis”. Shock and hypotension was defined as systolic 
blood pressure < 90 mm Hg.
The majority of instruments applied a simple “most 
severe” symptom to define the overall anaphylaxis sever-
ity [7, 10, 11, 14, 17, 18, 21, 23–25, 30], however 11 of 
the included instruments instead had a built-in algo-
rithm (marked Alg. in Table  2); Ewans5 [4] mandates 
at least one symptom from grade 1 (localized skin) or 
grade 2 (generalized skin) plus symptoms from GI/eyes/
nose to accomplish gr. 3. For Niggemann6 [29], Astier5 
[2], iFAAM5 [5], and Cox4 [27], grade 2 or grade 3 was 
directly linked to the number of included organs (one 
vs. multiple organs). Zee3 [9] calculates a none-linear 
severity index in tertiles, based on involved organs 
regardless of number of observed symptoms. Muel-
ler4 [13] mandates at least 2 milder symptoms plus the 
defining symptom to qualify for anaphylaxis > grade 1, 
whereas Pomphrey4 [20], Lockley3 [12] and ASCA6 
[28] included different numerical severity indexes, from 
which specific symptoms were recalculated to give an 
overall score. Due to absence of specific symptoms (type 
B error) for the latter 4 instruments, there was a marked 
reduction in the number of translatable challenges; e.g. 
for Mueller4 < 50% fulfilled the 2-or-more criteria. The 
simple “highest” possible symptom was therefore applied 
to these four instruments.
Statistics and translational algorithms
Comparison of severity, age, specific symptoms and 
type of allergen in Sampson5 was performed with ordi-
nal logistic regression. To compare the distribution of 
severity between instruments with 3 steps, Sampson5 
was reduced into three theoretical grade 3 scales; a scale 
milder than the original Sampson5 was obtained by 
merging grade 1 + 2 into 1, grade 3 + 4 into 2 and main-
taining grade 5 as a new grade 3 (i.e. grade 1, 2, 3, 4, 5 
become 1 + 2, 3 + 4, 5), a scale with similar severity dis-
tribution (1 + 2, 3, 4 + 5) and a scale with more severe 
severity distribution (1, 2 + 3, 4 + 5) than the original 
Sampson5. Using weighted kappa statistics, all 3-step-
instruments [6, 7, 9, 11, 12, 14, 17, 18, 24, 25, 30] were 
stepwise compared toward these 3 theoretical scales and 
the best agreement was identified, thereby ordering them 
into milder, similar or more severe than Sampson5. Simi-
lar, four theoretical 4-step-scales were constructed from 
Sampson5 for comparison between all instruments con-
taining 4 steps [10, 13, 20, 21, 23, 27]. Five-step scales [2, 
4, 5, 8] were directly compared to Sampson5, whereas 
the two instruments containing 6 steps [28, 29] were 
converted into 6 possible 5-step scales, which then were 
compared to Sampson5 using weighted kappa statistics. 
The cumulative distribution function (CDF) for all instru-
ments was plotted against the relative percentage sever-
ity of each instrument, i.e. as tertiles, quartiles, quintiles, 
and sextiles. The Area Under each CDF Curve (AUC) 
was calculated and the translatability was compared with 
nonparametric Spearman correlation test. WAO criteria 
[15] of anaphylaxis were applied to all challenges and 619 
challenges fulfilled these (see Table 1). Challenges identi-
fied as anaphylactic were then translated according to 
previous description and statistical analysis repeated 
for these. All calculations were performed in STATA14 
SE (Stata Corporation, College Station, TX, USA). The 
study was approved by the local board of Danish Data 
Protection Agency (license no. 2012-58-0018/journal no. 
16/31454).
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Results
Based on symptoms from all 2382 positive food chal-
lenges and 446 positive drug challenges, the 22 instru-
ments were translated from Sampson5. Translatability 
for foods and drugs for all instruments are presented in 
Table 2. Best translatability was found for Zee3, iFAAM5, 
ASCA6, SFFA4 and the NewEAACI3 [5, 9, 23, 28, 
30], were > 97.5% of all challenges could be translated, 
whereas only 56% of all challenges could be translated 
into Golden3 [11]. Mueller4, DSA3, Muraro3, Brown(A)3 
and Brown(B)3 [13, 17, 18, 24, 25] were significantly bet-
ter to translate food challenges than drug challenges, as 
opposed to Reismann3 and Hourihane(A)3 [7, 14]. There 
was a significant correlation between the translatability 
from Sampson5 and the number of steps in the receiv-
ing instruments for both foods  (rs = 0.57, p < 0.01) and 
drugs  (rs = 0.72 p < 0.005), meaning that instruments with 
5 steps less frequently had incomplete translation com-
pared to instruments only containing 3 or 4 steps. Only 
applying anaphylactic challenges increased the translat-
ability > 90% for all instruments, except 7 instruments on 
drug anaphylaxis [2, 6, 7, 10, 14, 18, 27]; Ring/Messmer4 
criteria [10] only translated 83% of drug anaphylaxis 
compared to 91%, when milder reactions were included.
The cumulative distribution function (CDF) for all 
instruments was plotted against the relative percent-
age severity of each instrument, i.e. the severity in a 
grade-3 instruments were presented as tertiles (i.e. 33, 
66 and 100%) and a grade 5 instruments as quintiles (i.e. 
20, 40, 60, 80, and 100%) (Fig. 2). Based on kappa statis-
tics, we could identify three possible scenarios; instru-
ments with left-skewed CDF and thereby overall milder 
severity-scoring than Sampson5 (Muraro3, Golden3, 
DSA3, Mueller4, Ring_Messmer4, SFFA4, Cox4, Ast-
ier5 and Niggemann6 [2, 10, 11, 13, 23–25, 27, 29]), 
similar distribution as Sampson5 (Zee3 and BrownB3 
[9, 18]) and instruments with a right-skewed CDF and 
hence a more severe symptom scoring than Sampson5 
(Reismann3, HourihaneB3, NewEAACI3, Pomphrey4, 
Ring_Behrendt4, and ASCA6 [6, 14, 20, 21, 28, 30]). Five 
instruments (HourihaneA3, Lockey3, BrownA3, Ewan5, 
and IFAAM5 [4, 5, 7, 12, 17]) showed different distribu-
tion on food than drug challenges compared to Samp-
son5 (red lines in Fig. 2).
The area under curve (AUC) for CDF was calculated 
(for Sampson5 marked in grey in Fig.  2). Correspond-
ing values of translatability (% translated symptoms 
compared to Sampson5) and AUC for foods and drugs 
are presented in Fig. 3, both for all symptoms and signs 
(Sampson grade 1 through 5) and for the 535 anaphylac-
tic food and 84 anaphylactic drug challenges. The relative 
severity compared to Sampson5 were for most instru-
ments unaffected when only anaphylactic reactions were 
included; only Reismann3, Pomphrey4, Brown(A)3 and 
Cox4 [14, 17, 20, 27] distributed food challenges milder, 
whereas Mueller4 [13] appraise anaphylactic food chal-
lenges as more severe. Reismann3 and Pomphrey4 [14, 
20] scored drug anaphylaxis milder than non-anaphylac-
tic reactions, indicating that they weighted milder symp-
toms more, than other instruments.
Discussion
The aim of this project was to compare existing severity 
instruments and identifying pros and cons among them, 
thereby forming a backbone for the development of a 
future instrument, which ideally should be retrograde 
compatible. To our knowledge, no study has applied 
multiple instruments on the same allergic reaction, and 
this paper is the first data-driven comparison of multiple 
anaphylaxis severity-scoring instruments, based on chal-
lenge-data from more than 12,000 titrated challenges.
The overall heterogeneity between included instru-
ments, i.e. their origin, structure and output was large; 
some instruments are purposed solely for single aller-
gens, e.g. peanut or bee venom, others developed exclu-
sively for specific populations, i.e. children and some 
to specific situations, e.g. after immunotherapy trials. 
The consequent extrapolation of instruments into non-
intended situations, lead to discrepancies; instruments 
developed to cope with hymenoptera reactions [11–14] 
overall had poor translatability and distributed severity 
differently compared to Sampson5, but were on the other 
hand not evaluated in venom anaphylaxis in this study. 
The only instrument intended on adverse drug reactions 
(Ring_Messmer4) [10] scored for food challenges milder 
than Sampson5.
Distributions in severity were different, some instru-
ments overestimated e.g. having more severe reactions 
than Sampson5 (Ring_Berend4, NewEAACI3 [21, 30]), 
others underestimated (Muraro3, Mueller4, Ring_Mess-
mer4 [10, 13, 25]), some scored food challenges more 
severe than drug challenges (Hourihane(A)3, iFAAM5 
[5, 7]), and others drug challenges more severe than food 
challenges (Brown(A)3, Evan5, Luckey3 [4, 12, 17]). Ana-
phylaxis represents the most ‘severe, life-threatening, 
generalized or systemic hypersensitivity reaction’ with 
multiple organs involved [31, 32], but scoring severity of 
an anaphylactic reaction in relation to exposure is com-
plex due to the overall nature of anaphylaxis (progression, 
timing and interaction of symptoms), titrated challenges 
(terminated after the first clear objective signs) and treat-
ment (immediately thereafter, hampering progression 
and overall severity). Therefore clear-cut anaphylactic 
reactions were identified and applied separately. Only 
22% of the included challenges could by definition be 
classified as anaphylaxis [15], however all instruments 
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included milder symptoms, such as urticaria (a grade 1–2 
reaction) not reflecting life-threatening anaphylaxis [29]. 
Some instruments only cover the most severe anaphylac-
tic reactions [11, 14], which is reflected in the translat-
ability of milder reactions, while others are designed for 
the whole spectrum of reactions [5, 8], thereby address-
ing anaphylaxis and milder reactions similar.
We found a reverse causality between the numbers of 
steps in instruments and the percentage of all, non-ana-
phylactic challenges to be translated, meaning that fine-
graded instruments were better in agreement with other 
tools concerning milder symptoms. All instruments 
could assess > 90% of the anaphylactic food challenges, 
whereas translatability for drug reactions are much more 
scattered; The explanation for this remains unclear, but 
as illustrated in Fig. 1, drug reactions manifest differently 
compared to food, with overrepresentation of non-ana-
phylactic skin symptoms. Surprisingly Ring/Messmer4 
[10], developed for adverse colloid volume substitu-
tion reactions, scored milder than all other instruments 
applied on drug reactions, and further had reduced trans-
latability on drug anaphylaxis compared to milder reac-
tions. Some instruments entirely [10] or partly [11] focus 
on cardio-vascular rather than respiratory symptoms and 
signs, whereas others report that lethality, especially in 
children, is a result of respiratory compromise [33] or a 
combination of both [17]. This is mainly interfering with 
milder reactions and not with anaphylaxis and together 
with the differences in translatability indicates that fine-
graded instruments mainly have their benefits among 
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milder symptoms, whereas all instruments cope with 
anaphylaxis as “most severe”.
All instruments are organ-based, i.e. the skin, respira-
tory, gastro-intestinal, cardio-vascular, and nervous sys-
tem, with symptoms classified into ordinal scales from 
3 to 6 incomparable steps, ranging from “present” over 
“mild/moderate/severe” to the 6-step comprehensive 
Japanese ASCA-system [28]. Anaphylaxis after acciden-
tal exposure in non-controlled settings outside a hospital 
necessitates a relatively simple classification system easy 
to apply retrospectively. Classifying severity in terms of 
different grades (mild/moderate/severe) may be more 
informative for patients and non-allergy specialists, espe-
cially if reduced to a limited number of categories. How-
ever, for research purposes it may be more useful to have 
a numerical score of severity with more gradations. The 
overall/total severity of a reaction is then either based on 
the highest/most severe symptoms [7, 8, 10, 11, 14, 17, 
21, 23–25], or calculated by different algorithms [6, 9, 12, 
13, 20, 28–30]. Overall, instruments applying an algo-
rithmic approach were neither superior in translatability 
nor distribution compared to Sampson5, with Zee3 [9] as 
only exception. However, a direct comparison of severity 
between most severe challenges revealed, that only half 
of grade 5 challenges in Sampson5 were translated into 
the most severe grade in Zee3, whereas milder reactions 
from multiple organs were converted into grade 3 in 
Zee3. Despite algorithms do not seem to add more infor-
mation, iFAAM5 [5] is currently developing a compre-
hensive data-driven numerical scoring system (nFASS), 
which will be interesting to compare among existing 
instruments in relation to the balance between informa-
tion gained and simplicity.
The retrospective application of instruments led to 
translational issues, where comparability and interpre-
tation of known symptoms were critical, and especially 
type B (symptom missing in comparing instruments) 
and type D errors (Sampson5 contained less informa-
tion than comparing instrument) caused discrepancies 
in the frequency of translation. Missing symptoms were 
an issue for all but one instrument [9], emphasizing the 
importance of a stable strategy to cope with these types 
of errors, which otherwise can lead to misclassification 
and thereby affect the overall severity of a reaction. In 
this study, symptoms not available were left untranslated, 
except for five instruments [2, 6, 10, 21, 29], where none-
recorded ‘fainting’ dramatically would reduce the num-
ber of most severe anaphylaxis. One way to overcome 
missing specific symptoms are “catch-all” definitions [2, 
4, 5, 9, 10, 12, 24, 30], i.e. all symptoms related to a spe-
cific organ, e.g. the “gastrointestinal tract”. Instruments 
including these have fewer type B arrows and thereby a 
higher translatability, in contrast to instruments with a 
predefined “symptom list”, which contains more informa-
tion for research purposes, and avoids the pitfall of over-
seeing especially milder symptoms.
Skin symptoms usually include pruritus, urticaria, 
angioedema, flush/rash in 1–2 dichotomous outcomes. 
GI symptoms consist both of subjective symptoms 
(OAS, nausea, and abdominal pain) and objective signs 
(emesis and diarrhea). Brown(A)3 [17] found a direct 
link between GI symptoms and hypotensive anaphy-
laxis, whereas Niggemann6 [29] claims that GI symptoms 
are over-represented, which is reflected in Niggemann6 
being milder compared to Samspon5 both after food, 
where GI symptoms are expectedly predominant, but 
surprisingly also after drug challenges. Cardio-vascular 
symptoms are characterized by a change in heart rate 
(from tachycardia to cardiac arrest) and degrees of hypo-
tension, where only few instruments have an exact defi-
nition [11, 17, 18, 25, 28]. Neurological symptoms are 
less consistent with grades of anxiety and consciousness 
(from reduced activity level to total loss of conscious-
ness). Niggemann6 [29] claims that subjective symptoms 
such as anxiety, malaise, weakness or dizziness should 
not form the basis for grading an allergic reaction, how-
ever 70% (77/110) of our challenges with neurologi-
cal subjective symptoms also have clear-cut objective 
signs from other organs. Terminating a challenge based 
on neurological symptoms is therefore rare and can be 
avoided by strict clinical stop-criteria. The biggest dis-
crepancies are found in respiratory symptoms; some 
instruments only apply airway obstruction (defined as 
asthma, cyanosis, or respiratory arrest [8]), symptoms 
from upper airways, i.e. nose and from eyes are covered 
by some [8, 20, 25] and are excluded by others [10, 13, 
17]. The interpretation of the respiratory system as one 
system including nose, pharynx, larynx, and bronchial is 
lacking, and especially symptoms from tongue and phar-
ynx are vaguely mentioned. The compression of ‘cough, 
hoarseness, dysphagia’, and ‘wheezing, asthma, dyspnea, 
cyanosis’ into two overall ‘laryngeal’ and ‘bronchial’ cat-
egories, and the lack of ‘stridor’, a seldom but adrenalin-
requiring laryngeal symptom, hamper Sampson5 [8], 
which have now prompted a change of in our department 
to facilitate this.
The incomplete translatability and the different number 
of steps among the instruments make the severity distri-
bution difficult to compare. No standardized or validated 
method exists to compare multiple heterogeneous scor-
ing systems; some instruments (iFAAM5, Niggemann6, 
ASCA6, SFFA4, Ring-Behrend4, NewEAACI3 [5, 21, 23, 
28–30] have high translatability i.e. percentage trans-
lated while others have a similar distribution of severity 
(Brown(B)3 [18]). The paired kappa comparison probably 
does not reflect the situation, where two clinical settings 
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intend to compare severity on two different populations, 
but it is the methodologically correct way to asses this in 
our retrospective study. By applying the CDF-curve, we 
assumed that severity obtained under standard challenge 
conditions was normally (Gaussian) distributed. A linear 
relationship between the grades, i.e. fixed and equal dis-
tance between steps, is also assumed but hypothetical.
The simplified distribution of instruments in reference 
to Sampson5 place them into 3 categories; milder, similar 
or more severe than Sampson5. Sampson5 was original 
applied at our sitting for historical reasons, mainly due to 
the high numbers of pediatric food challenges performed 
in our clinic. We do not claim that any of the instruments 
is better or worse to score severity of anaphylaxis, nor 
that Sampson5 is the gold standard. This simply identifies 
the difference between instruments, which reflects their 
heterogeneous etiology, and should be considered when 
comparing existing scoring systems for severity in ana-
phylaxis. This also emphasize, that instruments applied 
beyond their initial purpose have limitations, especially 
embracing milder reactions, and might reflect altered 
distribution of severity.
Conclusion
We found a reverse causality between the numbers of 
grades an instrument span and the percentage of non-
anaphylactic challenges to be translated, whereas ana-
phylaxis more easily is translated between instruments. 
The distributions in severity were different; some over-
estimate e.g. having more severe reactions than Samp-
son5 [21, 30], whereas others under-estimate [10, 13, 
25]. There is no consistency between food and drug 
challenge severity distribution; some scored food chal-
lenges more severe than drug challenges [5, 7] and others 
drug challenges more severe than food [4, 12, 17]. Most 
instruments appraise milder symptoms identical to ana-
phylaxis, whereas few weighted them more [14, 17, 20, 
27] or less severe [13]. Instruments developed to cope 
with hymenopteran reactions [11–14] overall had poor 
translatability and distributed differently compared to 
Sampson5. Drug challenges are complicated to compare 
[10], and finally algorithms do not add more informa-
tion, but compromise comparison of especially milder 
symptoms.
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